BC treatment was found to reduce NF-κB activity to half its basal level; furthermore, NF-κB activity, which had been elevated by more than 3-fold by gemcitabine at 40 ng/ml, markedly declined to a very low level when cells were co-treated with BC and gemcitabine (40 ng/ml) (Figure 4C). The gene discussed is NFKB1; the disease is breast cancer.